AUTOFLEET
18.3.2021 06:02:08 CET | Business Wire | Press release
Autofleet , a provider of AI-powered fleet optimization solutions, was selected by Keolis , a public transport operator, to provide its platform for an autonomous electric vehicle (AEV) project in Gothenburg, Sweden. Shuttle operation began on January 18, 2021 on behalf of local public transport authority Västtrafik. The autonomous shuttle service is the first project in an ongoing collaboration to utilize Autofleet’s platform for management of Keolis’ new mobility solutions.
The shuttle service, which is integrated into the city of Gothenburg’s public transportation network as line 56, will serve a route that covers industrial and residential sites using two autonomous electric shuttles manufactured by Navya. Designed to operate in conditions including sub-zero temperatures and snow, this autonomous electric shuttle service is the city’s most advanced mobility project to-date.
Autofleet’s platform aggregates and analyzes granular shuttle data through an integration with Navya’s API in real time to produce actionable insights for operators around the project’s performance. The interface tracks shuttles at the individual sensor level and continually provides data such as station and passenger usage, allowing Keolis to gain clear insights for optimization and improvement of the service. Automated notification and alerting capabilities keep the operational teams aware of field events as they occur. In addition, the Autofleet driver app allows safety operators to track and share reports with their team in a single interface.
Autofleet’s platform is agnostic to the vehicle manufacturer or vehicle type. For their continued work with Autofleet, Keolis is able to integrate autonomous shuttles and electric or internal combustion engine-powered vehicles into the platform, providing the transport operator with a single point of access for managing and scaling their deployments.
“Autofleet’s platform provides impactful data that allows us to measure KPIs, and in turn improve our toolkit of services for future projects,” said Scheherazade Zekri, Director of New Mobility Services at Keolis Group. “The company’s work with us is crucial for developing new autonomous shuttle services that better manage fleets and serve commuters.”
“Autofleet's goal is to implement sustainable mobility services and support the transition of asset heavy fleets to Vehicle as a Service providers.” said Kobi Eisenberg, CEO at Autofleet. “We are excited to partner with Keolis on this project in order to execute autonomous operations in extreme conditions serving the transportation needs of communities globally.”
Autofleet offers fleet owners and operators a platform to automate and optimize fleet management for organizations and has partnered with other global fleets and manufacturers including Avis Budget Group, Zipcar, Keolis and Suzuki. In April 2020, Autofleet announced a capital raise totaling $7.5 million from its Series A, led by MizMaa Ventures, and seed financing, led by Maniv Mobility.
About Autofleet
Autofleet provides the leading Vehicle-as-a-Service platform for fleets to optimize existing operations and to seamlessly launch new business models from existing assets. The platform leverages advanced machine-learning algorithms for demand prediction, optimized placement and matching, automated pit-stop management and in/de-fleeting, and more. For more information, please visit https://www.autofleet.io/ .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210317005879/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom